Robert L Jilka

US Patent:

8084023, Dec 27, 2011

Filed:

Jan 22, 2007

Appl. No.:

11/625763

Inventors:

Xiao-Dong Chen - Little Rock AR, US
Robert L. Jilka - Little Rock AR, US

Assignee:

The Board of Trustees of The University of Arkansas - Little Rock AR
The United States of America as represented by the Department of Veterans Affairs - Washington DC

International Classification:

C12N 5/06
C12M 1/00

US Classification:

424 931, 4353071, 435325, 435375

Abstract:

Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.

US Patent:

8388947, Mar 5, 2013

Filed:

Nov 16, 2011

Appl. No.:

13/297966

Inventors:

Xiao-Dong Chen - San Antonio TX, US
Robert L. Jilka - Little Rock AR, US

Assignee:

The Board of Trustees of the University of Arkansas - Little Rock AK
The United States of America as Represented by the Department of Veterans Affairs - Washington DC

International Classification:

A61K 35/28
A61K 35/12
C12N 5/0775
C12M 3/00
A61P 19/08

US Classification:

424 937, 435377, 4352891, 4353051, 4353041, 435366, 435354

Abstract:

Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.

US Patent:

20040224884, Nov 11, 2004

Filed:

Dec 22, 2003

Appl. No.:

10/743360

Inventors:

Stavros Manolagas - Little Rock AR, US
Robert Jilka - Little Rock AR, US
Robert Weinstein - Little Rock AR, US
Teresita Bellido - Little Rock AR, US

International Classification:

A61K038/29

US Classification:

514/012000

Abstract:

The invention as disclosed provides a method to increase bone mass without compromising bone strength or quality, through the administration to a host of a compound that binds to the estrogen or androgen receptor without causing hormonal transcriptional activation.

US Patent:

20040248078, Dec 9, 2004

Filed:

Dec 8, 2003

Appl. No.:

10/730751

Inventors:

Stavros Manolagas - Little Rock AR, US
Robert Jilka - Little Rock AR, US
Robert Weinstein - Little Rock AR, US
Teresita Bellido - Little Rock AR, US

Assignee:

Board of Trustees of the University of Arkansas

International Classification:

C12Q001/00

US Classification:

435/004000

Abstract:

The present invention demonstrates that glucocorticoid-induced bone disease is due to changes in the birth and death rate of bone cells using a murine model of glucocorticoid excess as well as bone biopsy specimens obtained from patients with glucocorticoid-induced osteoporosis. This invention demonstrates that glucocorticoid administration increases apoptosis of mature osteoblasts and osteocytes and decreases bone formation rate and bone mineral density accompanied by defective osteoblastogenesis and osteoclastogenesis in the bone marrow.

US Patent:

20050026223, Feb 3, 2005

Filed:

Apr 21, 2004

Appl. No.:

10/829028

Inventors:

Stavros Manolagas - Little Rock AR, US
Robert Jilka - Little Rock AR, US
Robert Weinstein - Little Rock AR, US
Teresita Bellido - Little Rock AR, US
Donald Bodenner - Little Rock AR, US
Stavroula Kousteni - Little Rock AR, US

Assignee:

The Board of Trustees of the University of Arkansas - Little Rock AR

International Classification:

G01N033/53
G01N033/567
A61K031/56

US Classification:

435007200, 514169000

Abstract:

The invention as disclosed provides a method to increase bone mass without compromising bone strength or quality, through the administration to a host of a compound that binds to the estrogen or androgen receptor without causing hormonal transcriptional activation.

US Patent:

6660468, Dec 9, 2003

Filed:

Oct 7, 1999

Appl. No.:

09/413958

Inventors:

Stavros C. Manolagas - Little Rock AR
Robert L. Jilka - Little Rock AR
Robert S. Weinstein - Little Rock AR
Teresita Bellido - Little Rock AR

Assignee:

Board of Trustees of the University of Arkansas - Little Rock AR

International Classification:

C12Q 100

US Classification:

435 4, 435 71

Abstract:

The present invention demonstrates that glucocorticoid-induced bone disease is due to changes in the birth and death rate of bone cells using a murine model of glucocorticoid excess as well as bone biopsy specimens obtained from patients with glucocorticoid-induced osteoporosis. This invention demonstrates that glucocorticoid administration increases apoptosis of mature osteoblasts and osteocytes and decreases bone formation rate and bone mineral density accompanied by defective osteoblastogenesis and osteoclastogenesis in the bone marrow.